Regen BioPharma Inc (RGBP) stock
RGBPOTCPharmaceutical PreparationsFiscal year ends September 30Also trades as RGBPP
$0.00+0.00 (+50.00%)
Close on Oct 19, 2026Market cap $92.33KP/E –Yield –
Regen BioPharma operating margin
Operating margin is operating income as a percentage of revenue.
Regen BioPharma's operating margin for the twelve months ending Jun 30, 2026 was -339.8%. For fiscal 2025 it was -143.1%, against -176.4% the year before. The highest annual figure on record is -143.1% in fiscal 2025.
Annual operating margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | -143.1% | +33.3 |
| FY2024 | Sep 30, 2024 | -176.4% | +114.0 |
| FY2023 | Sep 30, 2023 | -290.4% | −19.8 |
| FY2022 | Sep 30, 2022 | -270.6% | +57.5 |
| FY2021 | Sep 30, 2021 | -328.1% | −137.8 |
| FY2020 | Sep 30, 2020 | -190.3% | +497.7 |
| FY2019 | Sep 30, 2019 | -688.0% | +737.8 |
| FY2018 | Sep 30, 2018 | -1425.8% | +856.8 |
| FY2017 | Sep 30, 2017 | -2282.6% | +674.3 |
| FY2016 | Sep 30, 2016 | -2957.0% | −1926.1 |
| FY2015 | Sep 30, 2015 | -1030.9% | – |
Quarterly operating margin
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q3 FY2026CQ2 2026 | Jun 30, 2026 | 41.5% | +110.5 |
| Q2 FY2026CQ1 2026 | Mar 31, 2026 | -260.2% | −68.3 |
| Q1 FY2026CQ4 2025 | Dec 31, 2025 | -933.9% | −830.0 |
| Q4 FY2025CQ3 2025 | Sep 30, 2025 | -207.3% | −63.4 |
| Q3 FY2025CQ2 2025 | Jun 30, 2025 | -69.0% | +113.8 |
| Q2 FY2025CQ1 2025 | Mar 31, 2025 | -191.9% | −20.8 |
| Q1 FY2025CQ4 2024 | Dec 31, 2024 | -103.9% | +104.0 |
| Q4 FY2024CQ3 2024 | Sep 30, 2024 | -143.9% | −44.3 |
| Q3 FY2024CQ2 2024 | Jun 30, 2024 | -182.8% | −38.6 |
| Q2 FY2024CQ1 2024 | Mar 31, 2024 | -171.1% | +78.1 |
| Q1 FY2024CQ4 2023 | Dec 31, 2023 | -207.9% | +1258.2 |
| Q4 FY2023CQ3 2023 | Sep 30, 2023 | -99.5% | +209.5 |
| Q3 FY2023CQ2 2023 | Jun 30, 2023 | -144.2% | +44.1 |
| Q2 FY2023CQ1 2023 | Mar 31, 2023 | -249.2% | −2.0 |
| Q1 FY2023CQ4 2022 | Dec 31, 2022 | -1466.1% | −1129.7 |
| Q4 FY2022CQ3 2022 | Sep 30, 2022 | -309.0% | +87.4 |
| Q3 FY2022CQ2 2022 | Jun 30, 2022 | -188.3% | −42.8 |
| Q2 FY2022CQ1 2022 | Mar 31, 2022 | -247.2% | −199.9 |
| Q1 FY2022CQ4 2021 | Dec 31, 2021 | -336.4% | −269.0 |
| Q4 FY2021CQ3 2021 | Sep 30, 2021 | -396.5% | −328.3 |
| Q3 FY2021CQ2 2021 | Jun 30, 2021 | -145.5% | −85.9 |
| Q2 FY2021CQ1 2021 | Mar 31, 2021 | -47.3% | +96.1 |
| Q1 FY2021CQ4 2020 | Dec 31, 2020 | -67.4% | +423.9 |
| Q4 FY2020CQ3 2020 | Sep 30, 2020 | -68.2% | +615.1 |
| Q3 FY2020CQ2 2020 | Jun 30, 2020 | -59.6% | +442.6 |
| Q2 FY2020CQ1 2020 | Mar 31, 2020 | -143.4% | +698.1 |
| Q1 FY2020CQ4 2019 | Dec 31, 2019 | -491.3% | +233.7 |
| Q4 FY2019CQ3 2019 | Sep 30, 2019 | -683.3% | −558.0 |
| Q3 FY2019CQ2 2019 | Jun 30, 2019 | -502.2% | +0.6 |
| Q2 FY2019CQ1 2019 | Mar 31, 2019 | -841.5% | −164.7 |
| Q1 FY2019CQ4 2018 | Dec 31, 2018 | -725.0% | – |
| Q3 FY2018CQ2 2018 | Jun 30, 2018 | -125.2% | – |
| Q3 FY2017CQ2 2017 | Jun 30, 2017 | -502.8% | – |
| Q4 FY2016CQ3 2016 | Sep 30, 2016 | -676.9% | – |
See a number that looks wrong?